Revenue and Profit Growth - Revenue for Q1 2022 reached ¥2,061,708,856.14, representing a 165.28% increase compared to ¥777,189,276.45 in the same period last year[3] - Net profit attributable to shareholders was ¥499,398,084.81, up 223.59% from ¥154,330,479.55 year-on-year[3] - Net profit excluding non-recurring gains and losses was ¥486,390,519.38, reflecting a 275.76% increase from ¥129,442,396.10 in the previous year[3] - Total revenue for Q1 2022 reached ¥2,061,708,856.14, a significant increase of 165.28% compared to ¥777,189,276.45 in Q1 2021, driven by strong growth in both small molecule and emerging businesses[7] - Net profit for Q1 2022 was ¥499,398,084.81, reflecting a 223.59% increase from ¥154,329,304.12 in Q1 2021, primarily due to increased operating income and controlled costs[7] - Total profit reached 567,088,566.35, compared to 165,290,678.28 in the prior period, indicating a growth of about 243%[21] Cash Flow and Liquidity - Operating cash flow net amount was ¥204,607,061.83, a 103.27% increase compared to ¥100,659,080.60 in the same period last year[3] - Cash flow from sales of goods and services was ¥1,855,113,552.16, a 102.89% increase from ¥914,340,633.86, attributed to higher sales revenue[8] - Cash and cash equivalents at the end of Q1 2022 totaled ¥5,642,739,406.29, representing an increase of 183.51% from ¥1,990,297,803.19 in Q1 2021[8] - The cash flow from operating activities amounted to 1,855,113,552.16, compared to 914,340,633.86 in the previous period, showing an increase of around 103%[24] - The cash flow from investing activities resulted in a net outflow of -1,131,790,662.67, compared to -239,398,407.60 in the prior period, indicating a larger investment outflow[27] - Cash flow from financing activities generated a net inflow of 383,841,586.32, compared to 10,625,287.78 in the previous period, marking a substantial increase[29] Assets and Liabilities - Total assets as of March 31, 2022, were ¥16,389,663,097.90, an 8.14% increase from ¥15,156,297,270.34 at the end of the previous year[3] - Total liabilities increased to CNY 2,875,485,236.77 from CNY 2,546,285,945.92, reflecting a rise of approximately 12.9%[16] - The company's total assets reached CNY 16,389,663,097.90, up from CNY 15,156,297,270.34, indicating a growth of about 8.1%[44] - Non-current liabilities totaled CNY 384,070,747.82, compared to CNY 341,479,273.16 at the beginning of the year, reflecting an increase of approximately 12.4%[46] Shareholder Equity and Earnings Per Share - Shareholders' equity attributable to the company was ¥13,514,177,861.13, a 7.17% increase from ¥12,610,011,324.42 at the end of the previous year[3] - Basic earnings per share increased to ¥1.91, up 198.44% from ¥0.64 year-on-year[3] - Basic earnings per share for the current period were 1.91, compared to 0.64 in the previous period, indicating a significant increase[22] Research and Development - R&D expenses increased by 56.86% to ¥130,883,695.56, up from ¥83,440,733.89, as the company continued to invest in technological innovation[7] - Research and development expenses increased to CNY 130,883,695.56 from CNY 83,440,733.89, indicating a growth of approximately 56.7%[18] Other Financial Metrics - The company reported government subsidies amounting to ¥13,007,565.43 during the period[3] - Investment income surged to ¥11,660,530.17, a dramatic increase of 13,369.67% from a loss of ¥87,873.58, due to profits from joint ventures[7] - The company made significant investments totaling ¥1,099,322,000.00 in financial products, a 7,228.81% increase from ¥15,000,000.00 in the previous year[8] - The company reported a decrease in other comprehensive income after tax of -6,310,310.96, compared to an increase of 2,378,209.88 in the previous period[21]
凯莱英(06821) - 2022 Q1 - 季度财报